Is Entero Healthcar overvalued or undervalued?

As of 22 August 2025, Entero Healthcar's valuation grade has moved from attractive to very attractive, indicating a significant positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE Ratio of 52.27, an EV to EBITDA of 28.35, and a PEG Ratio of 0.37, which suggests strong growth potential relative to its price.
In comparison to its peers, Entero Healthcar's PE Ratio is notably higher than TCS at 22.42 and Infosys at 22.67, while its EV to EBITDA is also higher than TCS's 15.8 and Infosys's 14.88. Despite the high PE Ratio, the low PEG Ratio indicates that the stock may be undervalued given its growth prospects. Additionally, Entero Healthcar has outperformed the Sensex in the short term, with a 1-week return of 2.33% compared to the Sensex's 0.88%.